OMedLive

Online Events

Pediatric Neuroblastoma

Breast Cancer ASCO

HER2 Positive Breast Cancer

Multiple Myeloma

Invasive Fungal Infections

Hemophilia

Pancreatic Cancer

Colorectal Cancer

Chronic Lymphocytic Leukemia

Speakers

Pediatric Neuroblastoma

  • Navin Pinto, MD

    Navin Pinto, MD

    Navin Pinto, MD

    Associate Professor of Pediatrics

    Navin R. Pinto, MD, is an attending physician at Seattle Children's Hospital and an associate professor of pediatrics at the University of Washington School of Medicine. Dr Pinto’s interests and expertise focus on the use of genetic sequencing technologies to develop more personalized treatment strategies (pharmacogenomics) for children, adolescents, and young adults with solid tumors. He is an active member in numerous professional societies, has authored or co-authored articles published in various peer-reviewed journals, and is involved in several Phase I trials at Seattle Children’s Hospital. He earned his medical degree from the St. Louis University School of Medicine, and completed his pediatrics residency and pediatric hematology-oncology fellowship at the University of Chicago.

Breast Cancer ASCO

  • Harold J. Burstein, MD, PhD

    Harold J. Burstein, MD, PhD

    Harold J. Burstein, MD, PhD

    Medical Oncologist

    Harold J. Burstein, M.D., Ph.D. is an Associate Professor of Medicine at Harvard Medical School, and a medical oncologist at Dana-Farber Cancer Institute and Brigham & Women's Hospital. Dr. Burstein attended Harvard College, and earned his MD at Harvard Medical School where he also earned a PhD in immunology. He additionally has a master's degree in history of science from Harvard. He trained in internal medicine at Massachusetts General Hospital and in medical oncology at Dana-Farber.

    His clinical research interests include novel treatments for early- and advanced-stage breast cancer, and studies of quality of life and health behavior among women with breast cancer. Dr. Burstein has written widely on breast cancer in both traditional medical journals and on the web. Representative publications can be found in the New England Journal of Medicine, the Journal of Clinical Oncology, and other leading medical journals. He serves on international breast cancer committees including the NCCN Breast Cancer Panel, The St. Gallen Breast Cancer Panel, and the Alliance Breast Cancer Committee, and chairs the ASCO guidelines on endocrine therapy for breast cancer. Dr. Burstein an Associate Editor for Cancer Education at the Journal of Clinical Oncology.

HER2 Positive Breast Cancer

  • Eric Winer, MD

    Eric Winer, MD

    Eric Winer, MD

    Director, Breast Oncology Center

    Eric P. Winer, MD, is professor of medicine at Harvard Medical School, chief, Division of Women's Cancers, the Thompson Chair in Breast Cancer Research, and chief clinical strategy officer at Dana-Farber Cancer Institute. He is the leader of the Dana-Farber/Harvard Cancer Center Breast Program, and is the principal investigator/director of the Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer. Dr Winer has designed and led phase I, II, and III clinical trials, and collaborates closely with psychosocial researchers, health services researchers, and basic and translational scientists. His group at Dana-Farber conducts a broad array of breast cancer research with the goal of extending the lives of individuals with breast cancer, and minimizing suffering and morbidity from the disease.
  • Harold J. Burstein, MD, PhD

    Harold J. Burstein, MD, PhD

    Harold J. Burstein, MD, PhD

    Medical Oncologist

    Harold J. Burstein, M.D., Ph.D. is an Associate Professor of Medicine at Harvard Medical School, and a medical oncologist at Dana-Farber Cancer Institute and Brigham & Women's Hospital. Dr. Burstein attended Harvard College, and earned his MD at Harvard Medical School where he also earned a PhD in immunology. He additionally has a master's degree in history of science from Harvard. He trained in internal medicine at Massachusetts General Hospital and in medical oncology at Dana-Farber.

    His clinical research interests include novel treatments for early- and advanced-stage breast cancer, and studies of quality of life and health behavior among women with breast cancer. Dr. Burstein has written widely on breast cancer in both traditional medical journals and on the web. Representative publications can be found in the New England Journal of Medicine, the Journal of Clinical Oncology, and other leading medical journals. He serves on international breast cancer committees including the NCCN Breast Cancer Panel, The St. Gallen Breast Cancer Panel, and the Alliance Breast Cancer Committee, and chairs the ASCO guidelines on endocrine therapy for breast cancer. Dr. Burstein an Associate Editor for Cancer Education at the Journal of Clinical Oncology.

Multiple Myeloma

  • David Dingli, MD, PhD

    David Dingli, MD, PhD

    David Dingli, MD, PhD

    Professor of Medicine, Hematology

    David Dingli, MD, PhD, is a professor of medicine within the Division of Hematology, Department of Internal Medicine, at Mayo Clinic in Rochester, Minnesota. Dr Dingli’s clinical practice is dedicated to the care of patients with multiple myeloma and related disorders. His research aims to develop and optimize the use of replicating viruses for cancer therapy, with focus areas in mathematical models and clonal evolution in hematopoiesis. He has published over 200 articles and more than 200 abstracts, mostly related to multiple myeloma and its therapy. Dr Dingli earned his medical degree from the University of Malta Medical School in Guardamangia, Malta.
  • Shaji Kumar, MD

    Shaji Kumar, MD

    Shaji Kumar, MD

    Professor of Medicine, Hematology

    Shaji Kumar, MD, is a consultant in the Division of Hematology and professor of medicine at the Mayo Clinic in Rochester, Minnesota. His research efforts are directed toward studying novel treatment approaches in myeloma through clinical trials. He is currently principal investigator on multiple phase I, II, and III trials for plasma cell malignancies, and his laboratory has focused on the development of new agents for plasma cell malignancies, with a particular focus on the tumor microenvironment. Dr Kumar earned his MD from the All India Institute of Medical Sciences in New Delhi, completed a residency and fellowship at the Mayo School of Graduate Medical Education, and was a research associate and Mayo Foundation Scholar in multiple myeloma at the Dana-Farber/Harvard Cancer Center.

Invasive Fungal Infections

  • Dimitrios P. Kontoyiannis, MD, ScD, FACP, FIDSA

    Dimitrios P. Kontoyiannis, MD, ScD, FACP, FIDSA

    Dimitrios P. Kontoyiannis, MD, ScD, FACP, FIDSA

    Deputy Head, Division of Internal Medicine

    Dimitrios P. Kontoyiannis, MD, ScD, FACP, FIDSA is the Frances King Black Endowed Professor and Deputy Head-Research in the Division of Internal Medicine at The University of Texas MD Anderson Cancer Center. He is also an adjunct professor at Baylor College of Medicine and University of Houston College of Pharmacy in Houston Texas. He received his medical degree Summa Cum Laude from the National and Kapodistrian University of Athens in Greece. Dr. Kontoyiannis also completed a post-doctoral clinical research fellowship at the Section of Infectious Diseases at The University of Texas MD Anderson Cancer Center in Houston, TX, followed by training in Internal Medicine at Baylor College of Medicine in Houston, TX, where he served as a Chief Medical Resident. He was subsequently trained as a clinical fellow in Infectious Diseases at Massachusetts General Hospital and obtained a Master in Clinical Sciences from Harvard Medical School in Boston. He spent 3 years at the Whitehead Institute for Biomedical Sciences/Massachusetts Institute of Technology as a fellow in the Harvard MIT Clinical Investigators Training Program. Dr. Kontoyiannis has authored more than 450 peer-reviewed manuscripts and been invited to give over 150 lectures in international conferences and prestigious institutions in US and abroad. He serves as an associate editor for Mycoses and J of Infection and sits in the editorial Boards of Antimicrobial Agents & Chemotherapy, JID. Transplantation Infectious Diseases and he is a reviewer for several other peer-reviewed journals in Infectious Diseases ,Oncology and Hematology. An international expert in clinical and experimental mycology, and the top three most highly cited investigators in the area of mycology with over 450 peer reviwed manuscripts and over 27000 citations. He is a fellow of the American College of Physicians and the Infectious Diseases Society of America. He is the recipient of many awards such as the 2004 American Society for Microbiology award for Outstanding Research in the Pathogenesis of Microbial Diseases (mentor), the America's Top Physicians in from Consumer’s Research Council of America and The University of Texas MD Anderson Cancer Center 2004 Faculty E. N Cobb Scholar Award, Faculty Achievement Award, M. D. Anderson Cancer Center, 2007, The Distinguished Clinical Faculty Mentoring Award of at MD Anderson Cancer Center, 2012, The Billy Cooper Memorial award from The Medical Mycology Society of Americas (2013), America’s Top doctors (2015), The Drouhet Medal from the European Confederation of Medical Mycology (2015). He is the president elect of Immunocompromised Host Society (2016-2018).
  • George R. Thompson, MD

    George R. Thompson, MD

    George R. Thompson, MD

    Associate Professor of Medicine

    Dr. Thompson is Assistant Professor of Clinical Medicine at the University of California, Davis, School of Medicine with a joint appointment in the Departments of Medical Microbiology and Immunology, and Internal Medicine, Division of Infectious Diseases. Dr. Thompson specializes in the care of patients with invasive fungal infections and has research interest in fungal diagnostics and host immunogenetics. His current research focuses on the host-pathogen interaction of humans and both Coccidioides spp. (the agent of “Valley Fever”), and Cryptococcus spp. Dr. Thompson has served on the IDSA Journal Club which is a committee comprised of 12 panelists who select key papers for review and compose a summary of important articles that is published in the internationally disseminated monthly IDSA News. Additionally, he is a member of the Coccidioidomycosis Study Group Planning Committee, and as Co-chair of the Mycoses Study Group - a committee responsible for the development of content and dissemination of materials to practitioners across the United States, planning of the mycology content at yearly meetings (IDSA and ICAAC), and the design of clinical trials.
  • Nathan P. Wiederhold, PharmD, FCCP

    Nathan P. Wiederhold, PharmD, FCCP

    Nathan P. Wiederhold, PharmD, FCCP

    Associate Professor, Departments of Pathology & Medicine/Infectious Diseases

    Dr. Nathan P. Wiederhold is Associate Professor of Pathology and Medicine/Infectious Diseases at the University of Texas Health Science Center at San Antonio, and Adjoint Associate Professor of Pharmacy, at the University of Texas at Austin College of Pharmacy. Dr. Wiederhold received his Pharm.D. from the University of Texas at Austin in 2000, followed by pharmacy practice and infectious diseases clinical residencies at Barnes Jewish Hospital, St. Louis, Missouri. He then completed a two-year research fellowship in antifungal pharmacology/medical mycology at the University of Houston and UT MD Anderson Cancer in Houston, Texas. Dr. Wiederhold then joined the faculty of the University of Texas at Austin and the University of Texas Health Science Center at San Antonio in 2004. He then became the director of the Fungus Testing Laboratory in 2013. Dr. Wiederhold’s clinical and research areas include medical mycology, antifungal susceptibility and resistance, and antifungal therapeutic drug monitoring. He has over 100 peer-reviewed publications in this area, and his work has been supported by the National Institutes of Health, various professional organizations, and industry.
  • Thomas Patterson, MD

    Thomas Patterson, MD

    Thomas Patterson, MD

    Division Head and Division Chief, Infectious Diseases

    Dr. Thomas F. Patterson received his Bachelor of Arts degree from Baylor University, in Waco, Texas and his Medical Doctor from the University of Texas Medical School at Houston, Texas. He completed his internship and residency at Vanderbilt University Medical School, in Nashville, Tennessee and Yale-New Haven Hospital, and a fellowship in infectious diseases at Yale University School of Medicine, New Haven, Connecticut where he also served as an Assistant Professor of Medicine. Dr. Patterson currently is a Professor of Medicine and Chief, Division of Infectious Diseases at the University of Texas Health Science Center in San Antonio, Texas. He is also Director of the San Antonio Center for Medical Mycology. He has extensive experience in invasive fungal infections. His clinical and research interests focus on the diagnosis and treatment of fungal diseases particularly in immunocompromised hosts. He has been involved in developing new antifungal drugs and in clinical trials of new antifungal compounds. Dr. Patterson has published and lectured extensively on fungal infections. He has served as member of the American Board of Internal Medicine, Subspecialty Committee for Infectious Diseases, a Fellow of the American College of Physicians, Past-President of the Texas Infectious Disease Society, and current President, Immunocompromised Host Society.

Hemophilia

  • Regina B. Butler, RN

    Regina B. Butler, RN

    Regina B. Butler, RN

    Clinical Manager, Hematology

    Regina B. Butler, RN, is Hemophilia Clinical Manager at the Children’s Hospital of Philadelphia (CHOP) and Director of the Hemophilia Treatment Centers in Region III. In her role at CHOP, Ms Butler coordinates the care of over 450 children with bleeding disorders in collaboration with a large, multi-disciplinary team. She has served as a consultant to the Centers for Disease Control and Prevention (CDC) since 2000 to assist in the development of educational materials and curricula on bleeding disorders for health care providers, patients, and families. Ms Butler has had significant involvement in professional committees and organizations within the hemophilia community, including the National Hemophilia Foundation’s (NHF) Nursing Committee, where she served as a founding member and Chairperson, NHF’s Medical and Scientific Advisory Council, and Maternal and Child Health Bureau Executive Committee. She is the former U.S. representative to the World Federation of Hemophilia (WFH) Nursing Committee and served as a member of its Communications Committee. Ms Butler has published numerous papers on hemophilia, patient/family education, nursing education, and nursing perspectives on hemophilia care and HIV risk reduction. She has presented locally, nationally and internationally on a variety of topics in hemophilia care.
  • Brenda Riske, RN, MSN, MBA, MPA

    Brenda Riske, RN, MSN, MBA, MPA

    Brenda Riske, RN, MSN, MBA, MPA

    Director of Strategic Operations, Hemophilia and Thrombosis Center

    Brenda Riske, RN, MSN, MBA, MPA, is Regional Coordinator/Administrator, Mountain States Hemophilia Network, and Director, Strategic Planning, at the University of Colorado Hemophilia & Thrombosis Center. Over the past 30 years, Ms Riske has worked in the area of hemophilia as a clinician, administrator, and clinical research manager. She has been active in national organizations that include the National Hemophilia Foundation, the Centers for Disease Control and Prevention (CDC), and the Health Resources Services Administration (HRSA)/Maternal and Child Health Bureau. She chaired the provider curriculum development committee for the Blood Clot Disorder Association, and has served as member of the Hemophilia Utilization Group Study (HUGS) Steering Committee since 2008. Ms Riske is also a member of the Board of the Partners in Hemophilia Education, a national training program for clinical staff at hemophilia treatment centers, where she serves on the subcommittee developing a credentialing program for nurses in hemophilia treatment centers. She has published articles in numerous peer-reviewed publications, including the Journal of Medical Economics, Haemophilia, and Transfusion.

Pancreatic Cancer

  • Eileen M. O'Reilly, MD

    Eileen M. O'Reilly, MD

    Eileen M. O'Reilly, MD

    Associate Director for Clinical Research, David M. Rubenstein Center for Pancreatic Cancer Research

    Eileen M. O’Reilly, MD, is the associate director for clinical research for the David M. Rubenstein Center for Pancreatic Cancer Research, is an attending physician and member at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York, and is professor of medicine at Weill Medical College of Cornell University. Dr O’Reilly received her medical degree at Trinity College (Dublin University) in Ireland, where she was born, and completed her residency training in Ireland and fellowship training at MSKCC. Pancreatic and hepatobiliary malignancies are the major focus of her research and clinical activities. Her research initiatives include integration of molecular and genetic-based therapies for the treatment of pancreatic cancer, along with development of adjuvant and neoadjuvant therapies and identification of biomarkers that may be used to select therapy. Dr O’Reilly teaches and mentors oncology fellows (national and international), junior faculty, residents and house staff, and has numerous teaching and other awards. She is the principal investigator of multiple phase I, II and III trials in pancreatic cancer, and has authored/co-authored multiple articles, editorials, and book chapters. Dr O’Reilly’s other institutional responsibilities include associate chairpersonship of MSKCC’s Institutional Review & Privacy Board (IRB), membership of the Research Council, and chair of the Continuing Medical Education (CME) committee. Nationally Dr O’Reilly is the chair of the NCI Pancreas Task Force, co-chair of the Alliance GI committee, and serves on the scientific advisory board of the Pancreatic Cancer Action Network, NCCN pancreas panel, board of the National Pancreas Foundation, and the ASCO IMT committee.
  • Tanios Bekaii-Saab, MD, FACP

    Tanios Bekaii-Saab, MD, FACP

    Tanios Bekaii-Saab, MD, FACP

    Section Chief, Gastrointestinal Oncology

    Tanios Bekaii-Saab, MD, FACP, is professor of medicine and pharmacy at The Ohio State University Comprehensive Cancer Center (OSUCCC), where he also is section chief, gastrointestinal oncology, and chair of the OSUCCC Gastrointestinal Disease Research Group. Dr Bekaii-Saab earned his medical degree at the American University of Beirut in Lebanon. He completed his internal medicine residency at the Indiana University Medical Center in Indianapolis, and hematology/oncology and clinical pharmacology fellowships at Tufts University-New England Medical Center in Boston. Dr Bekaii-Saab's research interests include experimental therapeutics/translational research focused on molecularly-targeted and immune-mediated therapies in gastrointestinal (GI) cancers, and more specifically, pancreatic and biliary cancers. He is the principal investigator on numerous clinical trials, including studies supported through research grants from the National Cancer Institute (NCI) and the National Comprehensive Cancer Network (NCCN). Additionally, Dr Bekaii-Saab has authored or co-authored articles in several publications that include the Journal of the National Cancer Institute, American Journal of Clinical Oncology, Cancer Chemotherapy and Pharmacology, and Drugs.

Colorectal Cancer

  • Bert H. O’Neil, MD

    Bert H. O’Neil, MD

    Bert H. O’Neil, MD

    Cusick Professor of Oncology

    Bert H. O’Neil, MD, is the Joseph W. and Jackie J. Cusick Professor of Oncology in the Department of Medicine at the Indiana University School of Medicine in Indianapolis, and director of the Gastrointestinal Cancer Research and Phase I Clinical Trials Program at the Indiana University Simon Cancer Center. His primary area of expertise is in gastrointestinal cancers, with a particular concentration on pancreatic, colorectal and hepatocellular carcinomas, and has expertise in targeting new drugs to specific molecular targets on tumors. Dr O’Neil earned his medical degree from the University of California, Los Angeles School of Medicine, and completed his internal medicine residency and fellowship in hematology/oncology at the University of California, San Francisco. He is currently a member of the American Society of Clinical Oncology and is section reviewer: gastrointestinal malignancies, for UpToDate. Dr O’Neil has authored numerous journal articles and chapters in text books, and has served as an ad hoc reviewer for publications that include the Journal of Clinical Oncology, Cancer, Oncology, Lancet Oncology, Gastroenterology, American Journal of Oncology, and Annals of Oncology.
  • Andrea Cercek, MD

    Andrea Cercek, MD

    Andrea Cercek, MD

    Assistant Attending Physician

    Andrea Cercek, MD, is a board-certified medical oncologist who specializes in the treatment of patients with gastrointestinal cancers, particularly colorectal and appendix cancer, and those with peritoneal mesothelioma. She specializes in both systemic chemotherapy and regional chemotherapy given directly into the liver or the peritoneal cavity. Dr Cercek’s research focuses on the development of new therapies for patients, including molecular-based therapies to improve the outcomes for patients with metastatic disease. Dr Cercek is currently an assistant attending physician at Memorial Sloan-Kettering Cancer Center in New York. She earned her medical degree from New York Medical College, completed an internal medicine residency New York-Presbyterian Hospital/Weill Cornell Medical Center, and hematology/oncology fellowships at Memorial Sloan-Kettering Cancer Center.
  • Wasif Saif, MD

    Wasif Saif, MD

    Wasif Saif, MD

    Professor of Medicine; Director, GI Oncology Program

    Wasif M. Saif, MD, is professor of medicine, director of the Gastrointestinal Oncology Program, and program leader for Experimental Therapeutics, Department of Medicine, at Tufts University School of Medicine and Tufts Medical Center in Boston, Massachusetts. Dr Saif specializes in caring for patients with gastrointestinal malignancies; in particular, pancreatic and colorectal cancers. Over the last two decades, his research efforts have focused on the developing novel agents and treatment approaches for the treatment of cancer. As part of this effort, Dr Saif has worked as the principal investigator of multiple national and international studies investigating novel agents in the treatment of GI cancers. His research interest focuses on cancer pharmacology, pharmacogenetics, cancer drug development, and clinical investigations. Dr Saif graduated from King Edward Medical University, Lahore, Pakistan. He completed his internal medicine residency at the University of Connecticut School of Medicine in Farmington, and a medical oncology fellowship at the National Cancer Institute, NIH, in Bethesda, Maryland, and the National Naval Medical Center, Bethesda. Dr Saif also completed a hematology fellowship at the National Heart, Lung, and Blood Institute (NHLBI), NIH, in Bethesda. After the clinical fellowship, he became a junior investigator in the Investigational Drug Branch, NCI, where he worked in the Gastrointestinal Malignancies Section. Dr Saif is a member of the American Society of Clinical Oncology, American Society for Pharmacology and Experimental Therapeutics, and many others. He has published over 450 peer-reviewed articles about cancer treatment and research, over 80 abstracts and 20 book chapters, and serves on the editorial board of over 20 peer-reviewed cancer journals.

Chronic Lymphocytic Leukemia

  • John C. Byrd, MD

    John C. Byrd, MD

    John C. Byrd, MD

    D. Warren Brown Chair of Leukemia Research

    John C. Byrd, MD, is a nationally known researcher and clinical specialist in leukemia and other hematologic malignancies at Ohio State’s Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute. He is the head of the division of hematology, is a professor of medicine and medicinal chemistry, and holds the D. Warren Brown Chair in Leukemia Research. He received his MD from the University of Arkansas for Medical Sciences, completed a residency and fellowship at Walter Reed Army Medical Center, and a fellowship at Johns Hopkins University. Dr Byrd runs a highly translational laboratory focused on drug development in CLL and related lymphoproliferative disorders, and has been part of the successful development of multiple therapeutics in acute myeloid leukemia and CLL. He has more than 375 publications in the area of leukemia and experimental therapeutics research.
  • Jennifer R. Brown, MD, PhD

    Jennifer R. Brown, MD, PhD

    Jennifer R. Brown, MD, PhD

    Director, CLL Center

    Jennifer R. Brown, MD, PhD, is the director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and is an associate professor of medicine at Harvard Medical School in Boston. She earned her MD and PhD in molecular genetics from Harvard Medical School, served as an internal medicine intern and resident at Massachusetts General Hospital, and competed a fellowship in hematology and medical oncology at Dana-Farber Cancer Institute. Dr Brown has been instrumental in the clinical development of both idelalisib and ibrutinib, leading to their regulatory approvals in CLL, as well as in the description of the somatic mutation profile of CLL. She has published numerous scientific papers, is an active member of the CLL Research Consortium, and serves on the Alliance Leukemia and Leukemia Correlative Science Committees as well as the NIH Cancer Biomarkers Study Section.

OMedLive Speakers

  • Navin Pinto, MD

    Navin Pinto, MD

    Navin Pinto, MD

    Associate Professor of Pediatrics

    Navin R. Pinto, MD, is an attending physician at Seattle Children's Hospital and an associate professor of pediatrics at the University of Washington School of Medicine. Dr Pinto’s interests and expertise focus on the use of genetic sequencing technologies to develop more personalized treatment strategies (pharmacogenomics) for children, adolescents, and young adults with solid tumors. He is an active member in numerous professional societies, has authored or co-authored articles published in various peer-reviewed journals, and is involved in several Phase I trials at Seattle Children’s Hospital. He earned his medical degree from the St. Louis University School of Medicine, and completed his pediatrics residency and pediatric hematology-oncology fellowship at the University of Chicago.
  • Harold J. Burstein, MD, PhD

    Harold J. Burstein, MD, PhD

    Harold J. Burstein, MD, PhD

    Medical Oncologist

    Harold J. Burstein, M.D., Ph.D. is an Associate Professor of Medicine at Harvard Medical School, and a medical oncologist at Dana-Farber Cancer Institute and Brigham & Women's Hospital. Dr. Burstein attended Harvard College, and earned his MD at Harvard Medical School where he also earned a PhD in immunology. He additionally has a master's degree in history of science from Harvard. He trained in internal medicine at Massachusetts General Hospital and in medical oncology at Dana-Farber.

    His clinical research interests include novel treatments for early- and advanced-stage breast cancer, and studies of quality of life and health behavior among women with breast cancer. Dr. Burstein has written widely on breast cancer in both traditional medical journals and on the web. Representative publications can be found in the New England Journal of Medicine, the Journal of Clinical Oncology, and other leading medical journals. He serves on international breast cancer committees including the NCCN Breast Cancer Panel, The St. Gallen Breast Cancer Panel, and the Alliance Breast Cancer Committee, and chairs the ASCO guidelines on endocrine therapy for breast cancer. Dr. Burstein an Associate Editor for Cancer Education at the Journal of Clinical Oncology.
  • Eric Winer, MD

    Eric Winer, MD

    Eric Winer, MD

    Director, Breast Oncology Center

    Eric P. Winer, MD, is professor of medicine at Harvard Medical School, chief, Division of Women's Cancers, the Thompson Chair in Breast Cancer Research, and chief clinical strategy officer at Dana-Farber Cancer Institute. He is the leader of the Dana-Farber/Harvard Cancer Center Breast Program, and is the principal investigator/director of the Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer. Dr Winer has designed and led phase I, II, and III clinical trials, and collaborates closely with psychosocial researchers, health services researchers, and basic and translational scientists. His group at Dana-Farber conducts a broad array of breast cancer research with the goal of extending the lives of individuals with breast cancer, and minimizing suffering and morbidity from the disease.
  • David Dingli, MD, PhD

    David Dingli, MD, PhD

    David Dingli, MD, PhD

    Professor of Medicine, Hematology

    David Dingli, MD, PhD, is a professor of medicine within the Division of Hematology, Department of Internal Medicine, at Mayo Clinic in Rochester, Minnesota. Dr Dingli’s clinical practice is dedicated to the care of patients with multiple myeloma and related disorders. His research aims to develop and optimize the use of replicating viruses for cancer therapy, with focus areas in mathematical models and clonal evolution in hematopoiesis. He has published over 200 articles and more than 200 abstracts, mostly related to multiple myeloma and its therapy. Dr Dingli earned his medical degree from the University of Malta Medical School in Guardamangia, Malta.
  • Shaji Kumar, MD

    Shaji Kumar, MD

    Shaji Kumar, MD

    Professor of Medicine, Hematology

    Shaji Kumar, MD, is a consultant in the Division of Hematology and professor of medicine at the Mayo Clinic in Rochester, Minnesota. His research efforts are directed toward studying novel treatment approaches in myeloma through clinical trials. He is currently principal investigator on multiple phase I, II, and III trials for plasma cell malignancies, and his laboratory has focused on the development of new agents for plasma cell malignancies, with a particular focus on the tumor microenvironment. Dr Kumar earned his MD from the All India Institute of Medical Sciences in New Delhi, completed a residency and fellowship at the Mayo School of Graduate Medical Education, and was a research associate and Mayo Foundation Scholar in multiple myeloma at the Dana-Farber/Harvard Cancer Center.
  • Dimitrios P. Kontoyiannis, MD, ScD, FACP, FIDSA

    Dimitrios P. Kontoyiannis, MD, ScD, FACP, FIDSA

    Dimitrios P. Kontoyiannis, MD, ScD, FACP, FIDSA

    Deputy Head, Division of Internal Medicine

    Dimitrios P. Kontoyiannis, MD, ScD, FACP, FIDSA is the Frances King Black Endowed Professor and Deputy Head-Research in the Division of Internal Medicine at The University of Texas MD Anderson Cancer Center. He is also an adjunct professor at Baylor College of Medicine and University of Houston College of Pharmacy in Houston Texas. He received his medical degree Summa Cum Laude from the National and Kapodistrian University of Athens in Greece. Dr. Kontoyiannis also completed a post-doctoral clinical research fellowship at the Section of Infectious Diseases at The University of Texas MD Anderson Cancer Center in Houston, TX, followed by training in Internal Medicine at Baylor College of Medicine in Houston, TX, where he served as a Chief Medical Resident. He was subsequently trained as a clinical fellow in Infectious Diseases at Massachusetts General Hospital and obtained a Master in Clinical Sciences from Harvard Medical School in Boston. He spent 3 years at the Whitehead Institute for Biomedical Sciences/Massachusetts Institute of Technology as a fellow in the Harvard MIT Clinical Investigators Training Program. Dr. Kontoyiannis has authored more than 450 peer-reviewed manuscripts and been invited to give over 150 lectures in international conferences and prestigious institutions in US and abroad. He serves as an associate editor for Mycoses and J of Infection and sits in the editorial Boards of Antimicrobial Agents & Chemotherapy, JID. Transplantation Infectious Diseases and he is a reviewer for several other peer-reviewed journals in Infectious Diseases ,Oncology and Hematology. An international expert in clinical and experimental mycology, and the top three most highly cited investigators in the area of mycology with over 450 peer reviwed manuscripts and over 27000 citations. He is a fellow of the American College of Physicians and the Infectious Diseases Society of America. He is the recipient of many awards such as the 2004 American Society for Microbiology award for Outstanding Research in the Pathogenesis of Microbial Diseases (mentor), the America's Top Physicians in from Consumer’s Research Council of America and The University of Texas MD Anderson Cancer Center 2004 Faculty E. N Cobb Scholar Award, Faculty Achievement Award, M. D. Anderson Cancer Center, 2007, The Distinguished Clinical Faculty Mentoring Award of at MD Anderson Cancer Center, 2012, The Billy Cooper Memorial award from The Medical Mycology Society of Americas (2013), America’s Top doctors (2015), The Drouhet Medal from the European Confederation of Medical Mycology (2015). He is the president elect of Immunocompromised Host Society (2016-2018).
  • George R. Thompson, MD

    George R. Thompson, MD

    George R. Thompson, MD

    Associate Professor of Medicine

    Dr. Thompson is Assistant Professor of Clinical Medicine at the University of California, Davis, School of Medicine with a joint appointment in the Departments of Medical Microbiology and Immunology, and Internal Medicine, Division of Infectious Diseases. Dr. Thompson specializes in the care of patients with invasive fungal infections and has research interest in fungal diagnostics and host immunogenetics. His current research focuses on the host-pathogen interaction of humans and both Coccidioides spp. (the agent of “Valley Fever”), and Cryptococcus spp. Dr. Thompson has served on the IDSA Journal Club which is a committee comprised of 12 panelists who select key papers for review and compose a summary of important articles that is published in the internationally disseminated monthly IDSA News. Additionally, he is a member of the Coccidioidomycosis Study Group Planning Committee, and as Co-chair of the Mycoses Study Group - a committee responsible for the development of content and dissemination of materials to practitioners across the United States, planning of the mycology content at yearly meetings (IDSA and ICAAC), and the design of clinical trials.
  • Nathan P. Wiederhold, PharmD, FCCP

    Nathan P. Wiederhold, PharmD, FCCP

    Nathan P. Wiederhold, PharmD, FCCP

    Associate Professor, Departments of Pathology & Medicine/Infectious Diseases

    Dr. Nathan P. Wiederhold is Associate Professor of Pathology and Medicine/Infectious Diseases at the University of Texas Health Science Center at San Antonio, and Adjoint Associate Professor of Pharmacy, at the University of Texas at Austin College of Pharmacy. Dr. Wiederhold received his Pharm.D. from the University of Texas at Austin in 2000, followed by pharmacy practice and infectious diseases clinical residencies at Barnes Jewish Hospital, St. Louis, Missouri. He then completed a two-year research fellowship in antifungal pharmacology/medical mycology at the University of Houston and UT MD Anderson Cancer in Houston, Texas. Dr. Wiederhold then joined the faculty of the University of Texas at Austin and the University of Texas Health Science Center at San Antonio in 2004. He then became the director of the Fungus Testing Laboratory in 2013. Dr. Wiederhold’s clinical and research areas include medical mycology, antifungal susceptibility and resistance, and antifungal therapeutic drug monitoring. He has over 100 peer-reviewed publications in this area, and his work has been supported by the National Institutes of Health, various professional organizations, and industry.
  • Thomas Patterson, MD

    Thomas Patterson, MD

    Thomas Patterson, MD

    Division Head and Division Chief, Infectious Diseases

    Dr. Thomas F. Patterson received his Bachelor of Arts degree from Baylor University, in Waco, Texas and his Medical Doctor from the University of Texas Medical School at Houston, Texas. He completed his internship and residency at Vanderbilt University Medical School, in Nashville, Tennessee and Yale-New Haven Hospital, and a fellowship in infectious diseases at Yale University School of Medicine, New Haven, Connecticut where he also served as an Assistant Professor of Medicine. Dr. Patterson currently is a Professor of Medicine and Chief, Division of Infectious Diseases at the University of Texas Health Science Center in San Antonio, Texas. He is also Director of the San Antonio Center for Medical Mycology. He has extensive experience in invasive fungal infections. His clinical and research interests focus on the diagnosis and treatment of fungal diseases particularly in immunocompromised hosts. He has been involved in developing new antifungal drugs and in clinical trials of new antifungal compounds. Dr. Patterson has published and lectured extensively on fungal infections. He has served as member of the American Board of Internal Medicine, Subspecialty Committee for Infectious Diseases, a Fellow of the American College of Physicians, Past-President of the Texas Infectious Disease Society, and current President, Immunocompromised Host Society.
  • Regina B. Butler, RN

    Regina B. Butler, RN

    Regina B. Butler, RN

    Clinical Manager, Hematology

    Regina B. Butler, RN, is Hemophilia Clinical Manager at the Children’s Hospital of Philadelphia (CHOP) and Director of the Hemophilia Treatment Centers in Region III. In her role at CHOP, Ms Butler coordinates the care of over 450 children with bleeding disorders in collaboration with a large, multi-disciplinary team. She has served as a consultant to the Centers for Disease Control and Prevention (CDC) since 2000 to assist in the development of educational materials and curricula on bleeding disorders for health care providers, patients, and families. Ms Butler has had significant involvement in professional committees and organizations within the hemophilia community, including the National Hemophilia Foundation’s (NHF) Nursing Committee, where she served as a founding member and Chairperson, NHF’s Medical and Scientific Advisory Council, and Maternal and Child Health Bureau Executive Committee. She is the former U.S. representative to the World Federation of Hemophilia (WFH) Nursing Committee and served as a member of its Communications Committee. Ms Butler has published numerous papers on hemophilia, patient/family education, nursing education, and nursing perspectives on hemophilia care and HIV risk reduction. She has presented locally, nationally and internationally on a variety of topics in hemophilia care.
  • Brenda Riske, RN, MSN, MBA, MPA

    Brenda Riske, RN, MSN, MBA, MPA

    Brenda Riske, RN, MSN, MBA, MPA

    Director of Strategic Operations, Hemophilia and Thrombosis Center

    Brenda Riske, RN, MSN, MBA, MPA, is Regional Coordinator/Administrator, Mountain States Hemophilia Network, and Director, Strategic Planning, at the University of Colorado Hemophilia & Thrombosis Center. Over the past 30 years, Ms Riske has worked in the area of hemophilia as a clinician, administrator, and clinical research manager. She has been active in national organizations that include the National Hemophilia Foundation, the Centers for Disease Control and Prevention (CDC), and the Health Resources Services Administration (HRSA)/Maternal and Child Health Bureau. She chaired the provider curriculum development committee for the Blood Clot Disorder Association, and has served as member of the Hemophilia Utilization Group Study (HUGS) Steering Committee since 2008. Ms Riske is also a member of the Board of the Partners in Hemophilia Education, a national training program for clinical staff at hemophilia treatment centers, where she serves on the subcommittee developing a credentialing program for nurses in hemophilia treatment centers. She has published articles in numerous peer-reviewed publications, including the Journal of Medical Economics, Haemophilia, and Transfusion.
  • Eileen M. O'Reilly, MD

    Eileen M. O'Reilly, MD

    Eileen M. O'Reilly, MD

    Associate Director for Clinical Research, David M. Rubenstein Center for Pancreatic Cancer Research

    Eileen M. O’Reilly, MD, is the associate director for clinical research for the David M. Rubenstein Center for Pancreatic Cancer Research, is an attending physician and member at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York, and is professor of medicine at Weill Medical College of Cornell University. Dr O’Reilly received her medical degree at Trinity College (Dublin University) in Ireland, where she was born, and completed her residency training in Ireland and fellowship training at MSKCC. Pancreatic and hepatobiliary malignancies are the major focus of her research and clinical activities. Her research initiatives include integration of molecular and genetic-based therapies for the treatment of pancreatic cancer, along with development of adjuvant and neoadjuvant therapies and identification of biomarkers that may be used to select therapy. Dr O’Reilly teaches and mentors oncology fellows (national and international), junior faculty, residents and house staff, and has numerous teaching and other awards. She is the principal investigator of multiple phase I, II and III trials in pancreatic cancer, and has authored/co-authored multiple articles, editorials, and book chapters. Dr O’Reilly’s other institutional responsibilities include associate chairpersonship of MSKCC’s Institutional Review & Privacy Board (IRB), membership of the Research Council, and chair of the Continuing Medical Education (CME) committee. Nationally Dr O’Reilly is the chair of the NCI Pancreas Task Force, co-chair of the Alliance GI committee, and serves on the scientific advisory board of the Pancreatic Cancer Action Network, NCCN pancreas panel, board of the National Pancreas Foundation, and the ASCO IMT committee.
  • Tanios Bekaii-Saab, MD, FACP

    Tanios Bekaii-Saab, MD, FACP

    Tanios Bekaii-Saab, MD, FACP

    Section Chief, Gastrointestinal Oncology

    Tanios Bekaii-Saab, MD, FACP, is professor of medicine and pharmacy at The Ohio State University Comprehensive Cancer Center (OSUCCC), where he also is section chief, gastrointestinal oncology, and chair of the OSUCCC Gastrointestinal Disease Research Group. Dr Bekaii-Saab earned his medical degree at the American University of Beirut in Lebanon. He completed his internal medicine residency at the Indiana University Medical Center in Indianapolis, and hematology/oncology and clinical pharmacology fellowships at Tufts University-New England Medical Center in Boston. Dr Bekaii-Saab's research interests include experimental therapeutics/translational research focused on molecularly-targeted and immune-mediated therapies in gastrointestinal (GI) cancers, and more specifically, pancreatic and biliary cancers. He is the principal investigator on numerous clinical trials, including studies supported through research grants from the National Cancer Institute (NCI) and the National Comprehensive Cancer Network (NCCN). Additionally, Dr Bekaii-Saab has authored or co-authored articles in several publications that include the Journal of the National Cancer Institute, American Journal of Clinical Oncology, Cancer Chemotherapy and Pharmacology, and Drugs.
  • Bert H. O’Neil, MD

    Bert H. O’Neil, MD

    Bert H. O’Neil, MD

    Cusick Professor of Oncology

    Bert H. O’Neil, MD, is the Joseph W. and Jackie J. Cusick Professor of Oncology in the Department of Medicine at the Indiana University School of Medicine in Indianapolis, and director of the Gastrointestinal Cancer Research and Phase I Clinical Trials Program at the Indiana University Simon Cancer Center. His primary area of expertise is in gastrointestinal cancers, with a particular concentration on pancreatic, colorectal and hepatocellular carcinomas, and has expertise in targeting new drugs to specific molecular targets on tumors. Dr O’Neil earned his medical degree from the University of California, Los Angeles School of Medicine, and completed his internal medicine residency and fellowship in hematology/oncology at the University of California, San Francisco. He is currently a member of the American Society of Clinical Oncology and is section reviewer: gastrointestinal malignancies, for UpToDate. Dr O’Neil has authored numerous journal articles and chapters in text books, and has served as an ad hoc reviewer for publications that include the Journal of Clinical Oncology, Cancer, Oncology, Lancet Oncology, Gastroenterology, American Journal of Oncology, and Annals of Oncology.
  • Andrea Cercek, MD

    Andrea Cercek, MD

    Andrea Cercek, MD

    Assistant Attending Physician

    Andrea Cercek, MD, is a board-certified medical oncologist who specializes in the treatment of patients with gastrointestinal cancers, particularly colorectal and appendix cancer, and those with peritoneal mesothelioma. She specializes in both systemic chemotherapy and regional chemotherapy given directly into the liver or the peritoneal cavity. Dr Cercek’s research focuses on the development of new therapies for patients, including molecular-based therapies to improve the outcomes for patients with metastatic disease. Dr Cercek is currently an assistant attending physician at Memorial Sloan-Kettering Cancer Center in New York. She earned her medical degree from New York Medical College, completed an internal medicine residency New York-Presbyterian Hospital/Weill Cornell Medical Center, and hematology/oncology fellowships at Memorial Sloan-Kettering Cancer Center.
  • Wasif Saif, MD

    Wasif Saif, MD

    Wasif Saif, MD

    Professor of Medicine; Director, GI Oncology Program

    Wasif M. Saif, MD, is professor of medicine, director of the Gastrointestinal Oncology Program, and program leader for Experimental Therapeutics, Department of Medicine, at Tufts University School of Medicine and Tufts Medical Center in Boston, Massachusetts. Dr Saif specializes in caring for patients with gastrointestinal malignancies; in particular, pancreatic and colorectal cancers. Over the last two decades, his research efforts have focused on the developing novel agents and treatment approaches for the treatment of cancer. As part of this effort, Dr Saif has worked as the principal investigator of multiple national and international studies investigating novel agents in the treatment of GI cancers. His research interest focuses on cancer pharmacology, pharmacogenetics, cancer drug development, and clinical investigations. Dr Saif graduated from King Edward Medical University, Lahore, Pakistan. He completed his internal medicine residency at the University of Connecticut School of Medicine in Farmington, and a medical oncology fellowship at the National Cancer Institute, NIH, in Bethesda, Maryland, and the National Naval Medical Center, Bethesda. Dr Saif also completed a hematology fellowship at the National Heart, Lung, and Blood Institute (NHLBI), NIH, in Bethesda. After the clinical fellowship, he became a junior investigator in the Investigational Drug Branch, NCI, where he worked in the Gastrointestinal Malignancies Section. Dr Saif is a member of the American Society of Clinical Oncology, American Society for Pharmacology and Experimental Therapeutics, and many others. He has published over 450 peer-reviewed articles about cancer treatment and research, over 80 abstracts and 20 book chapters, and serves on the editorial board of over 20 peer-reviewed cancer journals.
  • John C. Byrd, MD

    John C. Byrd, MD

    John C. Byrd, MD

    D. Warren Brown Chair of Leukemia Research

    John C. Byrd, MD, is a nationally known researcher and clinical specialist in leukemia and other hematologic malignancies at Ohio State’s Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute. He is the head of the division of hematology, is a professor of medicine and medicinal chemistry, and holds the D. Warren Brown Chair in Leukemia Research. He received his MD from the University of Arkansas for Medical Sciences, completed a residency and fellowship at Walter Reed Army Medical Center, and a fellowship at Johns Hopkins University. Dr Byrd runs a highly translational laboratory focused on drug development in CLL and related lymphoproliferative disorders, and has been part of the successful development of multiple therapeutics in acute myeloid leukemia and CLL. He has more than 375 publications in the area of leukemia and experimental therapeutics research.
  • Jennifer R. Brown, MD, PhD

    Jennifer R. Brown, MD, PhD

    Jennifer R. Brown, MD, PhD

    Director, CLL Center

    Jennifer R. Brown, MD, PhD, is the director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and is an associate professor of medicine at Harvard Medical School in Boston. She earned her MD and PhD in molecular genetics from Harvard Medical School, served as an internal medicine intern and resident at Massachusetts General Hospital, and competed a fellowship in hematology and medical oncology at Dana-Farber Cancer Institute. Dr Brown has been instrumental in the clinical development of both idelalisib and ibrutinib, leading to their regulatory approvals in CLL, as well as in the description of the somatic mutation profile of CLL. She has published numerous scientific papers, is an active member of the CLL Research Consortium, and serves on the Alliance Leukemia and Leukemia Correlative Science Committees as well as the NIH Cancer Biomarkers Study Section.

Partners

Academic

Associations

Publishers